Sign In
Buy GUTS
$0.760
-0.0297 (-3.76%)
At Close: Jun 03, 2026
Fractyl Health to Participate in Upcoming September Investor Conferences
07:00am, Tuesday, 03'rd Sep 2024
BURLINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root cau
Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript
09:27pm, Wednesday, 14'th Aug 2024
Fractyl Health, Inc. (NASDAQ:GUTS ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-founder and CEO Lisa David
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
04:05pm, Wednesday, 14'th Aug 2024
Updated clinical results from German Real-World Registry demonstrate potential for Revita ® to meaningfully sustain weight loss and lower blood sugar for at least one-year post-treatment in a real-wo
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
07:00am, Wednesday, 07'th Aug 2024
BURLINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root caus
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
07:00am, Tuesday, 25'th Jun 2024
BURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
06:00am, Monday, 24'th Jun 2024
Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025 Co
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions
01:30pm, Sunday, 23'rd Jun 2024
Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p
Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript
10:37pm, Monday, 13'th May 2024
Fractyl Health, Inc. (NASDAQ:GUTS ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-founder and CEO Lisa Davidson
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
04:00pm, Monday, 13'th May 2024
Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivot
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
06:00am, Monday, 13'th May 2024
First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revit
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
06:00am, Wednesday, 08'th May 2024
BURLINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
06:00am, Tuesday, 07'th May 2024
BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of
At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita ® in patients with T2D in Germany At DDW, Fractyl Health will provide an oral presentation
